The Role of Pharmacovigilance in Successful Clinical Development
Most drugs that fail late, fail on efficacy. Safety is the next big reason. A JAMA Internal Medicine study tracked 640 novel therapeutics in late-stage trials. Of the 344 that failed, 17% failed because of safety concerns. A Tufts CSDD analysis of 812 compounds from the top 50 drug companies found an even higher share. […]